CytoSorbents announces independent DSMB recommends completion of STAR-T trial

CytoSorbents announced that it has received the recommendation from the independent Data and Safety Monitoring Board, DSMB, following the second scheduled safety review, to complete the pivotal Safe and Timely Antithrombotic Removal – Ticagrelor, STAR-T, trial as planned without any modifications. Dr. Efthymios N. Deliargyris, Chief Medical Officer of CytoSorbents commented, “We would like to thank the independent DSMB for the prompt review of the full unblinded dataset from the first 80 patients enrolled in the STAR-T trial. We are very pleased with the recommendation to continue the study as planned without modifications that now allows us to push towards the finish line in an expedited fashion. Based on the continued excitement and strong contributions from our U.S. and Canadian investigative sites, we continue to project that the trial, which remains blinded, will complete enrollment this summer.”